AI Consensus Investment Thesis
LONN: Lonza Group Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Lonza Group: 1-Year and 5-Year Forecast Outlook and Rating
Lonza Group (LONN) has an immediate No Action - Keep Monitoring consensus AI recommendation, based on 14 AI analysts.
The 1-year target is 611 CHF for , with -2.24% expected return (-1.78% including net dividends) and a PARTIAL SELL rating.
The 5-year target is 891 CHF for , with +42.56% expected return (+46.24% including net dividends) and a NEUTRAL rating.
Latest available market price: CHF 625, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0.52%. As of 2026-10-20.
Gross TTM: 0.8% · Two-year annualized gross: 0.72%.
Tax withholding assumption: 35% (CH). One-off special payments are excluded.
Original published assumption: 0.4% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Lonza Group Flagship Insight
Western Biomanufacturing Dominance Unlocks Structural Multiyear Free Cash Flow Inflection
High consensus confirms that maturing mammalian capacity, geopolitical reshoring, and portfolio simplification are driving structural margin expansion. While persistent currency drag and early-stage biotech financing remain frictions, cresting capital expenditure unlocks substantial free cash flow, solidifying an indispensable transatlantic biopharmaceutical tollbooth.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Warren Buffett (Value Purist)
Machiavelli (Insider)
Superintelligence (Anthropologist)
Universal Investor (Polymath)
Ray Dalio (Strategist)
Sherlock Holmes (Whistleblower)
Michael Burry (Vulture)
J.P. Morgan (Titan)
Elon Musk (Visionary)
Ran across these frontier AI models
Google Gemini 3.8 Flash
OpenAI GPT-6 Astra
Anthropic Claude Opus 5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Lonza Group: forecast questions
What is Lonza Group (LONN)'s 1-year price forecast?
Lonza Group's 1-year target is 611 CHF for Sept 2027. The current AI rating is PARTIAL SELL. The expected return from the recorded close is -2.24%, or -1.78% modeled return including net dividends. Latest available market price: CHF 625, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Lonza Group (LONN)'s 5-year price forecast?
Lonza Group's 5-year target is 891 CHF for Sept 2031. The current AI rating is NEUTRAL. The expected return from the recorded close is +42.56%, or +46.24% modeled return including net dividends. Latest available market price: CHF 625, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: CHF 625, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Lonza Group forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Lonza Group differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Lonza Group is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Lonza Group: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest CHF 10,000 in Lonza Group at the latest market close (20 Oct 2026): CHF 14,624 by Sept 2031.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
Benchmark comparison requires matching dated price and currency inputs.
* Return is calculated incl. 0.5% net dividend yield for Lonza Group.
The central economic thesis rests on an impending inflection in capital efficiency and operating leverage as an intensive five-year asset buildout matures. Following the acquisition of Vacaville's 330,000-liter mammalian capacity and the divestment of commoditized capsule operations, the business emerges as an optimized pure-play biopharmaceutical CDMO. Multi-year statutory accounting noise has obscured underlying operating income growth, while capital expenditure moderates from peak levels above 25% of revenue toward mid-teens. Commercial biologics outsourcing remains non-discretionary, insulated by prohibitive regulatory switching costs and Western reshoring mandates that drive long-term capacity absorption. Valuation sensitivity centers on the duration of cash conversion under restrictive global monetary policy, where higher discount rates penalize delayed cash flows. Furthermore, persistent Swiss franc real appreciation extracts ongoing translation drag against foreign-denominated customer contracts. Nevertheless, enterprise resilience is anchored by an unbreachable cGMP moat, premium pricing across complex antibody-drug conjugate synthesis, and significant balance-sheet deleveraging.
Key insights
- Cresting growth capital expenditures release substantial operating cash flow, converting accounting operating margins into durable, self-funding shareholder distributions.
- Western legislative biosecurity mandates create captive commercial demand, permanently elevating large-scale mammalian capacity utilization across US and Swiss hubs.
- Structural customer lock-in via validated regulatory master files insulates commercial commercialization from early-stage venture biotech funding volatility.
Lonza Group: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of CHF 625, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0.52%. As of 2026-10-20.
Gross TTM: 0.8% · Two-year annualized gross: 0.72%.
Tax withholding assumption: 35% (CH). One-off special payments are excluded.
Original published assumption: 0.4% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at CHF 546. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD; FX values are exchange rates.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Consensus target (CHF) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (CHF) | Optimistic Advisor Base Case (CHF) | S&P 500 benchmark (USD) | FX (USD/CHF) | |
| CHF 558 | +2.33% | -10.72% | -10.65% | Finalizing the consumer health divestment injects substantial upfront cash, eliminating short-term borrowing. Investors balance balance-sheet de-risking and pure-play portfolio clarity against pre-announced second-half maintenance phasing and persistent Swiss franc translational drag. | CHF 529 | CHF 567 | $750 | 0.84 | |
| CHF 575 | +3.01% | -8.00% | -7.81% | Full-year financial reporting confirms recurring operating margins within guided corridors, validating underlying manufacturing strength. Positive operating cash flow and initial third-party commercial contract announcements at Vacaville prompt constructive earnings revisions across healthcare equity desks. | CHF 513 | CHF 596 | $736 | 0.84 | |
| CHF 592 | +2.99% | -5.28% | -4.96% | Western biopharma clients accelerate commercial batch reservations under tightening supply-chain mandates. Commercial commissioning at Swiss drug-product sites adds visible capacity, offsetting lingering early-stage biotech venture funding softness with resilient commercial biologic volume. | CHF 529 | CHF 614 | $743 | 0.84 | |
| CHF 611 | +3.08% | -2.24% | -1.78% | Interim half-year results confirm accelerating operating cash conversion and steady mammalian utilization. Early client qualification milestones across transatlantic facilities reassure markets regarding technical integration timelines, driving measured valuation multiple recovery. | CHF 539 | CHF 638 | $755 | 0.84 | |
| CHF 627 | +2.67% | +0.32% | +0.93% | Multi-year commercial supply agreements for advanced antibody-drug conjugates expand contracted backlog into late decade. Favorable modality mix and capital expenditure discipline support solid quarterly operating performance heading into annual budget allocations. | CHF 539 | CHF 657 | $776 | 0.84 | |
| CHF 650 | +3.65% | +4.00% | +4.76% | Annual results demonstrate decisive free cash flow inflection as growth capital spending eases below historical thresholds. Management introduces expanded shareholder capital return initiatives, reinforcing investor confidence in normalized return on invested capital. | CHF 566 | CHF 684 | $787 | 0.83 | |
| CHF 663 | +2.02% | +6.08% | +7.00% | Vacaville transitions from legacy partner output into higher-margin commercial contracts, unlocking site operating leverage. High-barrier bioconjugate batch deliveries in Europe sustain solid gross margins despite persistent safe-haven currency translation penalties. | CHF 589 | CHF 704 | $803 | 0.83 | |
| CHF 682 | +2.84% | +9.12% | +10.21% | Mid-year reporting verifies stable underlying unit margins across mammalian suites, though competitive capacity announcements from rival contract manufacturers cap speculative multiple expansion. Fundamental performance remains anchored by non-discretionary blockbuster therapies. | CHF 624 | CHF 718 | $812 | 0.82 | |
| CHF 700 | +2.76% | +12.00% | +13.26% | Commercial scaling of integrated drug substance and sterile fill-finish operations broadens revenue capture per molecule. Contractual inflation pass-through clauses insulate operating income against utility and raw material cost fluctuations. | CHF 643 | CHF 740 | $839 | 0.82 | |
| CHF 721 | +2.99% | +15.36% | +16.81% | Financial reporting confirms sustained double-digit operating earnings growth and robust balance-sheet health. Organic cash generation comfortably funds selective specialized modality upgrades, cementing the franchise's standing among dependable European compounders. | CHF 663 | CHF 769 | $851 | 0.81 | |
| CHF 740 | +2.54% | +18.40% | +20.05% | Commercial launches of partnered oncology therapies drive high-capacity bioreactor scheduling. Incremental batch volumes generate operating leverage, supporting predictable quarterly appreciation even as overall European industrial equity momentum moderates. | CHF 683 | CHF 792 | $872 | 0.81 | |
| CHF 752 | +1.68% | +20.32% | +22.15% | Routine summer facility re-certifications and maintenance schedules produce standard seasonal volume consolidation. Pristine regulatory audit records and durable customer switching costs preserve firm contract pricing across all major campuses. | CHF 669 | CHF 808 | $886 | 0.81 | |
| CHF 771 | +2.56% | +23.36% | +25.40% | Specialized modalities capture commercial milestone payments as advanced cell and gene programs achieve clinical validation. Strong operational cash collection heading into fiscal year-end provides strategic flexibility for bolt-on capability investments. | CHF 696 | CHF 832 | $910 | 0.81 | |
| CHF 794 | +2.93% | +27.04% | +29.31% | Audited annual disclosures highlight free cash flow conversion exceeding half of operating profit, validating long-term capital reallocation. Progressive dividend expansion and steady equity repurchases continue to compound per-share intrinsic value. | CHF 717 | CHF 866 | $916 | 0.80 | |
| CHF 808 | +1.79% | +29.28% | +31.76% | Expanded automated bioprocessing suites achieve full run-rate throughput, enhancing batch yields and reducing labor intensity. Contract renewals with top-tier pharmaceutical sponsors incorporate multi-year take-or-pay volume protections. | CHF 727 | CHF 883 | $937 | 0.80 | |
| CHF 824 | +1.93% | +31.84% | +34.54% | Global healthcare procurement reviews maintain pricing discipline across mature biologics, but integrated antibody-drug conjugate complexity insulates overall corporate margins. Trading remains defensive and steady amidst shifting international macroeconomic conditions. | CHF 734 | CHF 901 | $947 | 0.80 | |
| CHF 840 | +2.01% | +34.40% | +37.33% | Commercial batch fulfillment finishes on schedule across European and North American facilities. High capacity utilization and negligible net debt support stable valuation multiples heading into annual portfolio rebalancing. | CHF 749 | CHF 919 | $970 | 0.79 | |
| CHF 861 | +2.45% | +37.76% | +40.95% | Full-year results confirm enduring mid-teens returns on capital, driven by mature mammalian assets and specialized synthesis platforms. Institutional capital continues accumulating the shares as a core defensive healthcare holding. | CHF 756 | CHF 946 | $980 | 0.79 | |
| CHF 875 | +1.65% | +40.00% | +43.42% | Capital expenditures stabilize at baseline maintenance levels, maximizing operational cash conversion. Incremental capacity additions operate under pre-contracted customer demand, generating predictable operating margins without speculative asset buildout. | CHF 764 | CHF 965 | $1,000 | 0.79 | |
| CHF 891 | +1.86% | +42.56% | +46.24% | The forecast horizon closes with the enterprise firmly positioned as an indispensable Western biomanufacturing infrastructure champion. Compounding commercial cash flows and durable regulatory moats secure a fully normalized, premium terminal valuation. | CHF 779 | CHF 984 | $1,012 | 0.79 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Lonza Group Stock Analysis & Scenarios Deep Dive
Lonza Group: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Prevailing market consensus treats the equity as an expensive healthcare contractor whose recovery has stalled following guided second-half margin moderation and historical post-pandemic destocking. Media and sell-side commentary remain fixated on high trailing price-to-earnings ratios distorted by statutory write-downs, while assuming that higher global interest rates will permanently starve early-phase biotech clinical pipelines and cap multi-year operating margins.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially underestimates value by confusing past peak capital expenditures and non-cash carve-out write-downs with operational deterioration. The market overlooks the dramatic structural shift underway: capital spending is tapering toward 16% of sales, while the consumer health divestment injects substantial cash to eliminate net debt. Crucially, consensus fails to model how captive onshoring demand under federal biosecurity policies will accelerate commercial mammalian utilization and expand normalized cash yields.
Repricing Catalyst
What could make the market recognize and close that gap? Formal closing of the consumer health divestment in late 2026 paired with the full-year 2026 earnings release provides the primary convergence catalyst. Demonstrating that core operating margins hold above 33% alongside a decisive swing to positive free cash flow will dismantle market skepticism, forcing sell-side analysts to revise forward cash conversion models upward.
Lonza Group: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Balanced
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Growing Awareness
Sentiment aligns around steady operational execution, but diverges sharply between fears of biotech funding freezes and conviction in captive reshoring demand. This positioning tension dictates whether valuation re-rates immediately or paces gradual capacity validation.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic setup presents a mixed backdrop that ultimately favors entrenched scale. Elevated central bank benchmark rates and tight liquidity constrain venture capital for speculative early-stage biotechs, creating demand friction in discovery pipelines. However, this is heavily countered by non-discretionary commercial medicine demand, contractual inflation escalators, and strategic sovereign biosecurity reshoring that insulates core biomanufacturing volumes.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive analytical debate centers on the speed and durability of free cash flow conversion. Bullish analyses argue that cresting capital expenditures, pure-play portfolio clarity, and captive onshoring demand will quickly lift core margins above 34% and unleash self-funding cash generation. Skeptical perspectives counter that Vacaville's complex technical transfers, prolonged biotech venture capital rationing, and safe-haven Swiss franc strength will delay real cash realization until late decade. Furthermore, analysts dispute whether competitive capacity from Asian and European rivals commissioning post-2028 will erode long-term pricing power. Tracking Vacaville contract onboarding and second-half free cash conversion will ultimately resolve this tension.
Lonza Group: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Biosecure Act Western Onshoring Mandate | Regulatory | +25% | +30% | Geopolitical decoupling and Western biosecurity legislation compel multinational pharmaceutical innovators to systematically transfer commercial pipelines away from Chinese manufacturing contractors. Entrenched transatlantic cGMP facilities absorb displaced mammalian and conjugate programs, establishing long-term take-or-pay contract backlogs, strengthening commercial batch pricing power, and expanding multi-year revenue visibility across the horizon. |
| Vacaville Bioreactor Capacity Commercialization | Competitive Positioning | +22% | +26% | Acquiring Genentech's 330,000-liter Vacaville site secures massive mammalian capacity at roughly one-third of greenfield construction cost. Phasing out legacy partner production in favor of proprietary, higher-margin third-party commercial contracts drives significant fixed-cost leverage, structurally elevating operating margins and compounding group operating income as site utilization crosses 80%. |
| Capital Expenditure Normalization Cash Harvest | Operational Efficiency | +18% | +21% | A multi-year investment supercycle that absorbed over 25% of annual sales is decisively cresting. As major mammalian, bioconjugation, and fill-finish complexes achieve regulatory commissioning, capital intensity moderates toward mid-teens. This disciplined transition converts past heavy construction spend into substantial recurring free cash flow, supporting balance-sheet deleveraging and shareholder distributions. |
| Antibody-Drug Conjugate Technological Moat | Innovation And Product | +16% | +20% | The clinical expansion of complex antibody-drug conjugates requires difficult cytotoxic linker synthesis, antibody conjugation, and sterile drug product handling under strict regulatory containment. Rare end-to-end capabilities spanning payload synthesis to aseptic filling create severe supplier bottlenecks, enabling premium batch pricing, exceptional gross margins, and expanding market share across next-generation oncology blockbusters. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Swiss Franc Structural Currency Penalty | Macroeconomic And Macrofinancial | -12% | -14% | Persistent safe-haven demand drives ongoing real appreciation of the Swiss franc against the US dollar and euro. Because over 80% of commercial revenue is invoiced abroad while significant technical overhead and corporate operations reside in Switzerland, foreign exchange translation friction continuously erodes nominal top-line growth and trims reported group earnings. |
| Prolonged High Rate Biotech Winter | Sector And Industry | -10% | -11% | Elevated central bank policy rates increase hurdle rates and restrict venture capital deployment into pre-revenue biotechnology innovators. Prolonged financing constraints lead emerging biopharma clients to defer exploratory pipelines and delay Phase I/II clinical trial reservations, creating persistent volume friction across early-development services and specialized therapeutic modality cleanrooms. |
| Vacaville Commercial Tech-Transfer Gestation | Operational Efficiency | -8.0% | -10% | Transitioning massive mammalian capacity from captive partner production to third-party commercial sponsors requires complex analytical comparability testing, pilot runs, and multi-quarter regulatory filings. This multi-year customer onboarding lag creates temporary facility overhead underabsorption, dampening near-term asset turnover and delaying peak return on invested capital from newly integrated assets. |
| Bioprocessing Input Cost Inflationary Friction | Operational Efficiency | -6.0% | -8.0% | Geopolitical volatility and cleanroom energy demands keep regional utility overhead, specialized single-use bioprocess bags, and chromatography resins structurally expensive. Although master service agreements feature contractual inflation-indexing mechanisms, quarterly administrative pass-through lags expose operating margins to temporary cost leakage during periods of volatile raw material and energy pricing spikes. |
Lonza Group: What Could Break or Accelerate the Thesis
Event Risk Score: Very Low 6/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Flagship Bioreactor Contamination Regulatory Halt | 18% | -28% | A severe microbial contamination, adventitious virus breach, or critical FDA Form 483 warning letter at a flagship mammalian hub like Vacaville or Visp would trigger mandatory production shutdowns. Remediating sterile cleanrooms, addressing client batch forfeitures, and managing regulatory audits would consume hundreds of millions in direct costs, stalling commercial releases and severely impairing institutional trust. |
| Big Pharma Modular In-Sourcing Wave | 21% | -22% | Major global pharmaceutical corporations could deploy surplus commercial cash flows to construct captive, automated internal manufacturing pods by 2028, reversing long-term outsourcing trends. Canceling third-party CDMO capacity reservations upon contract expiration would strand large-scale bioreactor suites with unabsorbed fixed depreciation overhead, precipitating severe industry-wide price discounting and multi-year return compression. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Mandatory Federal BIOSECURE Supply Sanctions | 34% | +28% | Congress or executive agencies could eliminate transition safe harbors, mandating an immediate cut-off of federal biopharma procurement linked to designated foreign CDMOs by 2027. This regulatory trigger would spark a panicked scramble among global pharmaceutical sponsors for compliant Western commercial mammalian bioreactor capacity. Lonza would command premium capacity reservation fees, driving operating margins beyond 36% and expanding annual free cash flow well above base-case projections. |
| Oncology ADC Commercial Mega-Blockbuster Surge | 26% | +24% | Simultaneous first-line regulatory approvals for multiple partnered antibody-drug conjugate candidates across major solid tumor indications between 2027 and 2029 could exhaust global bioconjugation capacity. Exclusive integrated supply agreements from payload synthesis to sterile fill-finish would maximize throughput across specialized suites, driving divisional operating margins above 42% and catalyzing an aggressive equity re-rating. |
Company Financial AnalysisLonza Group: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Lonza Group financials here.
Earnings and financials
Headline financial results presented a confusing picture that masked robust underlying manufacturing health. In fiscal 2025, the company posted an optical statutory net loss of 275 million Swiss francs despite full-year sales jumping 19.2% to 6.53 billion francs. Forensic inspection confirms this paper loss stemmed from non-cash accounting write-downs taken to prepare the consumer capsules business for sale, rather than operational decay. Underlying contract manufacturing is gathering powerful momentum. Continuing operations accelerated into the first half of 2026, delivering 3.37 billion francs in revenue and a 38.7% surge in net profit to 591 million francs. As one-off separation noise fades, high-margin commercial biologics are establishing a strong, recurring earnings foundation.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | CHF 6.5B | CHF -275M | CHF -204M |
| 2024 | CHF 5.5B | CHF 636M | CHF -143M |
| 2023 | CHF 6.7B | CHF 654M | CHF -263M |
| 2022 | CHF 6.2B | CHF 1.2B | CHF -852M |
| 2021 | CHF 5.4B | CHF 2.9B | CHF -124M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | >100x | TTM | Native | CHF / CHF |
| 2024 | 30.8x | TTM | Native | CHF / CHF |
| 2023 | 12.2x | TTM | Native | CHF / CHF |
| 2022 | 27.7x | Annual | Native | CHF / CHF |
| 2021 | 19.3x | Annual | Native | CHF / CHF |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Profitability is experiencing structural expansion as customer demand shifts heavily toward high-complexity biologic medicines. Operating margins rebounded to 21.2% in 2025, while continuing operations achieved core margins of 34.8% during the first half of 2026. This operational strength reflects fixed-cost dilution across expanding production suites and commanding pricing power in specialized antibody-drug conjugates. While standard factory maintenance will produce normal second-half seasonal moderation, structural margins remain firmly elevated. Jettisoning lower-margin consumer capsule products and filling large-scale bioreactors with proprietary client therapies establishes a durable operating margin floor above 33% over the multi-year planning horizon.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | CHF 1.4B | 21.2% | -4.2% |
| 2024 | CHF 1.1B | 19.9% | 11.6% |
| 2023 | CHF 854M | 12.7% | 9.7% |
| 2022 | CHF 1.3B | 21.7% | 19.5% |
| 2021 | CHF 819M | 15.1% | 54.4% |
Balance sheet and leverage
The balance sheet reflects conservative financial stewardship engineered to withstand external macro volatility. The business closed 2025 with a prudent debt-to-equity ratio of 0.50 and strong interest coverage exceeding eight times operating income, confirming that borrowing remains well controlled despite the scale of recent acquisitions. Financial flexibility will expand dramatically upon the final closing of the consumer capsules divestment. Upfront cash proceeds will substantially eliminate net debt, providing ample dry powder to navigate elevated global interest rates, fund selective high-tech manufacturing upgrades, and return cash to shareholders through buybacks without financial strain.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | CHF 4.5B | CHF 719M | CHF 3.8B net debt | CHF 3.8B | 2.21x |
| 2024 | CHF 5.1B | CHF 1.7B | CHF 4B net debt | CHF 3.4B | 1.52x |
| 2023 | CHF 3.1B | CHF 1.7B | CHF 1.7B net debt | CHF 1.5B | 1.77x |
| 2022 | CHF 2.6B | CHF 2.2B | CHF 1.2B net debt | CHF 363M | 1.85x |
| 2021 | CHF 2.7B | CHF 3.2B | CHF 1.2B net debt | CHF -435M | 2.50x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management has decisively concluded an aggressive five-year building boom that poured billions into stainless-steel bioreactors and cleanrooms. Between 2022 and 2024, capital spending absorbed between 21% and 26% of annual revenues, culminating in the 1.2 billion dollar purchase and modernization of the Vacaville site. This massive reinvestment deliberately restrained free cash flow to establish an unassailable manufacturing footprint ahead of global competitors. That intensive investment phase is now paying off. With major biologic suites fully qualified and capital intensity gliding toward mid-teens of sales, money previously consumed by construction will flow directly to the bottom line. This shift converts historical cash absorption into substantial, self-funding cash generation.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | CHF 1.4B | CHF 112M |
| 2024 | CHF 1.4B | CHF 102M |
| 2023 | CHF 1.6B | CHF 105M |
| 2022 | CHF 1.9B | CHF 95M |
| 2021 | CHF 1.3B | CHF 90M |
Behind the synthesisLonza Group: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The synthesized research demonstrates strong independent convergence on core operational mechanics: the five-year capital expenditure supercycle has crested, the carve-out of commoditized capsule operations provides immediate balance-sheet deleveraging, and geopolitical mandates increasingly redirect commercial biologics toward audited Western infrastructure. However, material analytical disagreements emerge regarding the velocity of free cash flow conversion, the drag of Swiss franc translation, and duration sensitivity in an elevated interest rate regime. Uncritical extrapolations of reported margins into immediate distributable cash fail scrutiny due to multi-quarter qualification cycles at Vacaville and ongoing capital requirements for sterile fill-finish lines. Opinions providing rigorous semiannual reconstructions, verified regulatory timetables, and clear distinctions between statutory accounting write-downs and recurring manufacturing cash receive top weight. Conversely, perspectives assuming instantaneous multiple expansion or overlooking early-stage biotech funding headwinds are moderated, ensuring the consensus reflects industrial reality rather than speculative multiple inflation.
All 14 opinions
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 8.5%
Exemplary primary verification reconstructing continuing semiannual revenue and identifying trailing aggregation errors. Rigorously differentiates operational free cash flow from post-interest distributable cash, providing an unvarnished assessment of peer capacity additions and valuation constraints that justifies a leading allocation.
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 8.0%
Provides exceptional independent evidence tracking statutory filings, legislative listings, and capital expenditure phasing. Discloses material valuation nuances, including duration sensitivity and rival capacity additions post-2028, balancing commercial mammalian scarcity against the delayed timing of cash conversion.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.5%
Accurately details commercial biologics demand elasticity and regulatory onshoring dynamics. Grounded balance-sheet analysis properly contextualizes conservative gearing. However, assumptions regarding flawless Vacaville commercial absorption slightly underestimate multi-quarter regulatory filing timelines required for new client drug master files.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.5%
Offers meticulous forensic accounting disentangling non-cash carve-out write-downs from recurring CDMO operating profits. The analysis of second-half margin seasonality and capacity qualification timing is highly credible, balancing pure-play multiple expansion against ongoing Swiss franc foreign exchange drag.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.5%
Delivers rigorous scrutiny of the gap between operational and distributable free cash flow, grounded in asset replacement values. Identifies legitimate risks regarding customer concentration in blockbuster therapies, though its terminal earnings growth assumptions lean somewhat conservative against verified biologics backlog expansion.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.5%
Establishes a robust through-cycle macroeconomic view, linking capital expenditure supercycle maturation to sovereign supply-chain reordering. Effectively balances long-term take-or-pay contract stability against early-phase venture funding headwinds, delivering a well-evidenced framework for normalized returns on capital.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.1%
Provides a disciplined counter-perspective emphasizing capital inertia, elevated trailing multiples, and multi-year depreciation friction. The evaluation accurately highlights delayed free cash flow realization, though it slightly understates the near-term margin support delivered by high-margin antibody-drug conjugate customer pipelines.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.1%
Constructs a compelling thesis on non-discretionary commercial medicine demand and high regulatory switching costs. While effectively identifying core operational resilience beneath temporary impairments, the projected multiple re-expansion is somewhat optimistic given prevailing high-rate sovereign yield pressures across European healthcare.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.1%
Thoroughly investigates geopolitical supply reallocation under federal biosecurity policies and transatlantic capacity dynamics. It captures the strategic moat of large-scale mammalian assets, though its assumption of rapid pricing power acceleration is slightly tempered by competitive Western capacity commissioning late-decade.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.1%
Skillfully reconciles post-earnings trading pullbacks with underlying capital expenditure normalization and portfolio reshaping. The assessment of Vacaville transition gestation lags is economically sound, maintaining prudent expectations for mid-term free cash flow recovery despite wider biotech funding constraints.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.6%
Identifies durable economic moats rooted in regulatory compliance and technical complexity across bioconjugates. The evaluation cleanly separates statutory portfolio write-downs from recurring CDMO earning power, though the timeline for third-party commercial batch onboarding at Vacaville is slightly ambitious.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.1%
Presents strong insight into bioreactor titer advancements cannibalizing legacy steel capacity. However, aggressive multiples and rapid deleveraging assumptions overlook contractual transition lags and the reality that customers require lengthy comparability protocols before shifting volume away from established mammalian infrastructure.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.1%
Articulates structural tailwinds from geopolitical supply-chain reorientation and portfolio simplification. While correctly identifying operational leverage in bioconjugates, its trajectory underweights the persistent translational currency friction of a strong Swiss franc against primary dollar and euro billing streams.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.1%
Presents a compelling perspective on Western manufacturing infrastructure consolidation and commercial biologics pricing power. However, projecting enterprise multiples past twenty times EBITDA discounts sovereign rate realities and understates early-stage biotech pipeline deferrals in specialized modalities.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Lonza Group forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web35 available sources from this batch (154 recorded). The first 15 are shown below; expand to read the rest.
- Federal Reserve Board - Federal Reserve issues FOMC statement federalreserve.gov
- Relay Therapeutics, Inc. - Form 10-Q - FY2026 sec.gov
- Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest... lonza.com
- Dividende LONZA GRP LONN, résultats et prévisions LONZA GRP, Cotation Bourse Swiss EBS Stocks - Boursorama boursorama.com
- Lonza Divests Capsules & Health Ingredients Business for $3 Billion • CHEManager is the market-leading medium for the management of the chemical and pharmaceutical industry chemanager-online.com
- U.S. Pharma Tariffs And MFN Become Law After April 2 Update clinicalleader.com
- Trump Administration Imposes Section 232 Tariffs on Patented Pharmaceutical Imports; Tiered Rate Structure Takes Effect Beginning July 31, 2026 | Crowell & Moring LLP crowell.com
- Earnings call transcript: Lonza H1 2026 profit gains fail to lift shares By Investing.com investing.com
- Lonza Group (LONN) Stock Forecast & Price Target - Investing.com investing.com
- Lonza H1 2026 slides: margin upgrade overshadowed by muted outlook By Investing.com investing.com
- Linklaters advises Lonza on divestment of its Capsules & Health Ingredients (CHI) business linklaters.com
- Lonza lifts margin target, repeats latter half of 2026 to be slower | live live.euronext.com
- https://www.lonza.com//-/media/Lonza/Lonzacom/investor-relations/Financial%20Presentations/2026_half-year_presentation lonza.com
- https://www.lonza.com//-/media/Lonza/Lonzacom/investor-relations/Financial%20Reports/2026_half-year_APM_report lonza.com
- https://www.lonza.com//-/media/Lonza/Lonzacom/investor-relations/Financial%20Reports/2026_half-year_report lonza.com
Show 20 more sources
- Lonza Delivered Strong H1 2026 Performance Across All Business Platforms and... lonza.com
- Lonza Delivers Strong Performance in Q1 2026 in Line with Expectations and... lonza.com
- Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully... lonza.com
- Lonza Expands HPAPI Capacity in Visp, Further Supporting its Position in... lonza.com
- Lonza Expands Strategic Collaboration with Leading US Biopharmaceutical Company lonza.com
- Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche lonza.com
- Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche lonza.com
- Lonza | Integrated Biologics lonza.com
- Lonza Further Strengthens US Manufacturing Presence with Addition of a... lonza.com
- Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance lonza.com
- BIOSECURE Act Becomes Law Limiting Grants With Biotechnology Companies of Concern lw.com
- Lonza Divests Capsules & Health Ingredients Business for $3 Billion - Nutraceuticals World nutraceuticalsworld.com
- Lonza divests capsules and health ingredients business for $2.2B in upfront cash | Pharma Manufacturing pharmamanufacturing.com
- BIOSECURE Act Enacted | Insights | Ropes & Gray LLP ropesgray.com
- Lonza To Divest Capsules & Health Ingredients Business To Lone Star Funds rttnews.com
- Samsung Biologics Reports Second Quarter 2026 Financial Results | Samsung Biologics samsungbiologics.com
- Lonza Accelerates Margin Expansion Two Years Ahead of Schedule as Vacaville Integration Delivers stocksfoundry.com
- WuXi AppTec’s 1260H Listing Brings the BIOSECURE Act Back to Center Stage thefdalawblog.com
- Lonza delivers strong 1st-half 2026 performance | The Pharmaletter thepharmaletter.com
- Lonza at Morgan Stanley conference: cdmo shift, growth and cash focus By Investing.com uk.investing.com
119 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-12-31–2026-06-30, 6 periods.
Currencies cited: CHF, USD (quote CHF; primary reporting CHF; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.